NASDAQ · SLN
Silence Therapeutics Plc American Depository Share
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SLN: Nov 5, 2026
Silence Therapeutics Plc American Depository Share is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.26. The reported EPS for the same quarter last year was $-0.45.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.26 | $-0.24 | $-0.27 | 3 |
| Dec 2026 | $-0.28 | $-0.24 | $-0.30 | 3 |
| Mar 2027 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Jun 2027 | $-0.36 | $-0.36 | $-0.36 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · NASDAQ.com- Zacks · Oct 20, 8:55 AM EDTDoes Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- RTTNews · Oct 19, 3:42 PM EDTBiotech Stocks Rally: SLN Soars 125%, WORX Jumps 105%, IRON Gains 41%(RTTNews) – Biotech and healthcare stocks surged on Monday, drawing investor attention to Silence Therapeutics' $1.3 billion acquisition deal, SCWorx's new healthcare agreement and Disc Medicine's positive Phase 3 trial results. The developments highlighted acquisition-driven ups
- RTTNews · Oct 19, 10:45 AM EDTSilence Therapeutics Stock Soars 126% On Merck KGaA Acquisition Deal(RTTNews) – Silence Therapeutics plc (SLN) is up 125.52 percent, gaining $10.90 to $19.58 on Monday. The surge follows a definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire Silence Therapeutics in an all-cash transaction with an enterprise value of $1.1 billion an
- Zacks · Oct 14, 8:35 AM EDTSilence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Silence Therapeutics (SLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversa
- Zacks · Oct 13, 11:00 AM EDTSilence Therapeutics (SLN) Upgraded to Buy: Here's WhySilence Therapeutics (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Aug 15, 2:59 AM EDTWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals(RTTNews) – This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts.
- Zacks · Aug 13, 9:55 AM EDTWall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- RTTNews · Aug 11, 6:31 AM EDTSilence Therapeutics Announces Public Offering Worth $150 Mln In American Depositary Shares(RTTNews) – Silence Therapeutics plc (SLN), a biotechnology company, announced a proposed public offering for $150 million worth of American Depositary Shares (ADSs).
- RTTNews · Aug 11, 4:05 AM EDTBiotech Stocks At 52-Week Highs – SLN +29% & ABCL +34% On Positive Trial Data, CPIX, CLDX, BDSX(RTTNews) – The following biotech stocks reached a 52-week high on August 10, 2026, driven by key catalysts such as positive quarterly reports or the release of promising results from clinical trials.
- MarketBeat · Aug 11, 1:01 AM EDTSilence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV TrialSilence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company’s plan to advance a quarterly dosing reg
- RTTNews · Aug 10, 10:20 AM EDTSilence Therapeutics Soars As Divesiran Meets Primary Goal In Phase 2 PV Study;Q2 Net Loss Narrows(RTTNews) – Silence Therapeutics plc (SLN), a clinical-stage biotechnology company, announced that the Phase 2 SANRECO trial of Divesiran in 48 phlebotomy-dependent patients with polycythemia vera met its primary and secondary goals. In addition, the company reported second-quart
- NASDAQ.com · Aug 10, 8:29 AM EDTPre-Market Most Active for Aug 10, 2026 : SPCX, ACHR, ABCL, SION, INTC, IPHA, SLN, CHMI, NOK, HZO, B, IONQThe NASDAQ 100 Pre-Market Indicator is down -31.07 to 29,691.23. The total Pre-Market volume is currently 110,469,046 shares traded.The following are the most active stocks for the pre-market session: Space Exploration Technologies Corp. (SPCX) is +2.99 at $136.10, with 9,630,42
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Silence Therapeutics Plc American Depository Share from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.